Skip to main content
Premium Trial:

Request an Annual Quote

Signal Genetics Debuts Array-Based Test for Multiple Myeloma

Premium

By Justin Petrone

Signal Genetics, a New York-based genetic testing firm, this month began offering the Myeloma Prognostic Risk Signature, or MyPRS, test, which was developed to help physicians guide treatment for individuals with multiple myeloma.

The firm is offering the test to physicians through a direct sales force and via select specialty commercial laboratories. The test, which is run on the Affymetrix GeneChip platform, will be performed at the company’s Clinical Laboratory Improvement Amendments-compliant laboratory in Little Rock, Ark., Signal said.

CEO Joe Hernandez said in a statement that MyPRS "uses the world’s largest outcomes database to correlate patient disease profiles, and provides additional insights to a patient’s specific gene expression profile." He said the firm's array-based gene expression test offers more detailed profiling information than the fluorescence in situ hybridization and cytogenetic-based assays that are currently on the market.

Signal acquired an exclusive license to the technology behind the new test from the University of Arkansas Medical Sciences earlier this year. The firm claims MyPRS can predict the stage of disease, calculate the odds of relapse, and lead physicians to the optimal treatment regimen for those suffering from myeloma.

In September, Signal said it would use the MyPRS testing platform in a multiple myeloma research program being conducted by Array BioPharma. Under the terms of that deal, Signal is providing Boulder, Colo.-based Array BioPharma with genetic information from patient samples in two upcoming clinical studies on an Array BioPharma drug candidate. It said at the time that the collaboration could lead to the development of "superior and personalized treatment options for myeloma patients."


Have topics you'd like to see covered in BioArray News? Contact the editor at jpetrone [at] genomeweb [.] com.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.